Procyon looks to milestones with new funding:
This article was originally published in Clinica
Canadian biotechnology company Procyon Biopharma has raised Can$10 million (US$6.5 million) through further public and private offerings. The Montreal-based company's products include the prognostic and diagnostic applications of prostate secretory protein (PSP94) and COLOPATH, a noninvasive screening test for colorectal cancer licensed to IMI.
You may also be interested in...
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by Europe’s brand industry. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.